公开(公告)号：US20220137067A1

公开(公告)日：2022-05-05

申请号：US17503122

申请日：2021-10-15

Applicant: Genentech, Inc.

Inventor： Alexis DeHaven DUNKLE ,  Jeongsup SHIM ,  Sahim Xavier WALLACE ,  Linda Git-Mon CHAN ,  Catherine CRUZ ,  Michael Thomas EBY

IPC: G01N33/68 ,  G01N33/50

Abstract: The present invention provides a cell-based assay for measuring antibody potency. Antigen, bound to a surface, is contacted with the antibody which in turn is contacted with a reporter cell. Compositions and kits are also contemplated.

公开(公告)号：US20220135701A1

公开(公告)日：2022-05-05

申请号：US17500741

申请日：2021-10-13

Applicant: Genentech, Inc.

Inventor： Wei-Ching LIANG ,  WeiYu Lin ,  Yan Wu ,  Minhong Yan

IPC: C07K16/40 ,  A61P35/00

Abstract: The present disclosure provides anti-MerTK antibodies and methods of use thereof. The methods comprise administering an anti-MerTK antibody or an immunoconjugate thereof.

公开(公告)号：US20220122690A1

公开(公告)日：2022-04-21

申请号：US17378651

申请日：2021-07-16

Applicant: GENENTECH, INC.

Inventor： Kai Liu ,  Nicolas Winston Lounsbury ,  William John Thrift ,  Adric Quade Broadwell ,  Lélia Yvonne Delamarre ,  Suchit Sushil Jhunjhunwala

IPC: G16B15/30 ,  G16B40/20 ,  G06N3/04 ,  A61K39/00 ,  G16H20/10

Abstract: Embodiments disclosed herein generally relate to using an attention-based machine learning model to generate an output that includes at least one of an interaction prediction for a target interaction, an interaction affinity prediction, or an immunogenicity prediction relating to a target interaction for a corresponding peptide-immunoprotein complex (IPC) combination. A target interaction may be between a peptide and an immunogenicity complex (IPC) such as, for example, a major histocompatibility complex (MHC), a T cell receptor (TCR), or both. A pharmaceutical composition may be identified, manufactured, and/or used that includes one or more peptides for which one or more target interactions are predicted to be more likely. Methods of treatment may be defined and/or used that include administration of such a pharmaceutical composition.

公开(公告)号：US20220111054A1

公开(公告)日：2022-04-14

申请号：US17483234

申请日：2021-09-23

Applicant: Genentech, Inc.

Inventor： Sandeep Yadav ,  Nidhi Doshi ,  Tamanna Shobha ,  Anthony Tomlinson ,  Amit Srivastava

IPC: A61K47/26

Abstract: The present disclosure provides polysorbate 20 compositions with particular fatty acid ester concentrations. In some embodiments, they may be used in pharmaceutical formulations, for example, to improve stability.

公开(公告)号：US20220106322A1

公开(公告)日：2022-04-07

申请号：US17644742

申请日：2021-12-16

Applicant: Genentech, Inc.

Inventor： Mark Edward Zak ,  Naomi S. Rajapaksa ,  Yun-Xing Cheng ,  Wei Li ,  Daniel G.M. Shore ,  F. Anthony Romero ,  Marian C. Bryan

IPC: C07D487/04 ,  C07D519/00

Abstract: Compounds and salts thereof that are useful as JAK kinase inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.

公开(公告)号：US20220098668A1

公开(公告)日：2022-03-31

申请号：US17553210

申请日：2021-12-16

Applicant: GENENTECH, INC.

Inventor： Michael Townsend ,  Alvernia Francesca Setiadi ,  Tracy Staton

IPC: C12Q1/6883 ,  G01N33/564 ,  A61K39/395 ,  C07K16/28 ,  C07K16/24

Abstract: The present invention concerns markers of multiple sclerosis, their use, and treatment with IL-17 antagonists, including IL-17 antibodies, of subjects with increased levels of such markers.

公开(公告)号：US20220098325A1

公开(公告)日：2022-03-31

申请号：US17473401

申请日：2021-09-13

Applicant: Genentech, Inc.

Inventor： Teemu T. JUNTTILA ,  Stuart LUTZKER

IPC: C07K16/32 ,  A61P35/00 ,  C07K16/28 ,  A61K45/06 ,  A61K39/395

Abstract: The present invention provides methods of treating of HER2-positive cancers (such as HER2-positive breast cancer and HER2-positive gastric cancers) using HER2 antibodies, such as a combination of a HER2 T cell-dependent bispecific antibody (TDB) with an additional HER2 antibody (e.g., trastuzumab).

公开(公告)号：US20220098318A1

公开(公告)日：2022-03-31

申请号：US17411638

申请日：2021-08-25

Applicant: Genentech, Inc.

Inventor： Raymond D. MENG ,  Robert Wenchen HSIEH ,  Namrata Srivastava PATIL ,  Sean Keith KELLEY ,  Karen Lynn KLING-MILLER ,  William Michael FLANAGAN

IPC: C07K16/28 ,  A61P35/00

Abstract: The invention provides methods of dosing for the treatment of cancers. In particular, provided are methods for treating human patients having cancer, such as a hematologic cancer, by administering a combination of an anti-TIGIT antagonist antibody and an anti-CD20 antibody or anti-CD38 antibody.

公开(公告)号：US20220089780A1

公开(公告)日：2022-03-24

申请号：US17411753

申请日：2021-08-25

Applicant: Genentech, Inc.

Inventor： Luc Desnoyers

IPC: C07K16/40 ,  G01N33/50 ,  A61K31/506 ,  A61K31/475 ,  A61K31/4196 ,  A61K31/138 ,  A61K31/565 ,  A61K31/4745 ,  A61K31/517 ,  A61K31/5685 ,  A61K38/17 ,  G01N33/74 ,  A61K39/395 ,  A61K45/06 ,  C07K14/71 ,  G01N33/574

Abstract: The invention concerns uses of anti-KLβ agents, and detection of KLβ and/or FGF19 and/or FGFR4.

公开(公告)号：US11279939B2

公开(公告)日：2022-03-22

申请号：US16143189

申请日：2018-09-26

Applicant: Genentech, Inc.

Inventor： Laetitia Malphettes ,  Andrew Snowden ,  Inn H. Yuk

IPC: C12N15/67 ,  C12N15/63

Abstract: The invention provides compositions and methods for regulating intracellular osmolarity in cells, e.g., in cultured cells, including in cultured cells in bioreactors. The invention provides nucleic acids comprising at least one osmo-responsive transcriptional regulatory element (OR-TRE), and cells, vectors, products of manufacture, artificial organs or implants and the like containing an osmo-responsive transcriptional regulatory element (OR-TRE).